Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 15/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 12/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24827851 | 0.88 | HSD17B10 (0.42) | CYP2D6HSD17B10CYP1A2ALDH1A1ALOX15 | |
| SCHEMBL17404868 | 0.86 | CYP3A4 (0.36) | CYP2D6HSD17B10CYP1A2ALDH1A1ALOX15 | |
| SCHEMBL24827913 | 0.85 | CYP3A4 (0.36) | CYP2D6HSD17B10CYP1A2ALDH1A1TSHR | |
| SCHEMBL13131096 | 0.76 | USP2 (0.40) | CYP2D6HSD17B10CYP1A2TSHRCYP3A4 | |
| SCHEMBL9906447 | 0.75 | SMN1; SMN2 (0.42) | CYP2D6CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL11947832 | 0.73 | CYP2C9 (0.59) | CYP2D6CYP1A2ALDH1A1TSHRCYP3A4 | |
| SCHEMBL9906408 | 0.73 | MEN1 (0.40) | CYP2D6CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL12459039 | 0.73 | MEN1 (0.40) | CYP2D6CYP1A2ALDH1A1CYP2C19SMN1; SMN2 | |
| SCHEMBL16624956 | 0.73 | GRIN2D (0.34) | USP2 | |
| SCHEMBL17404870 | 0.72 | MEN1 (0.40) | HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573956-B2 | Compounds as dual inhibitors of phosphodiesterases and histone deacetylases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-02-21 | — | — | US | disclosed |
| US-9573956-B2 | Compounds as dual inhibitors of phosphodiesterases and histone deacetylases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-02-21 | — | — | US | disclosed |
| US-20160002246-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002246-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | PDE1A, HDAC1, HDAC2 | CYP2D6 2544/4885HSD17B10 97/4885CYP1A2 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.